The role of insulin-like growth factor-1 in development of coronary no-reflow and severity of coronary artery disease in patients with acute myocardial infarction

Ibrahim Faruk Akturk¹, Ahmet Arif Yalcin¹, Ismail Biyik², Nihan Turhan Caglar¹, Nilgun Isiksacan⁴,
Cetin Sarikamis¹, Fatih Uzun¹, Omer Celik¹, Ilker Murat Caglar⁵

¹Department of Cardiology, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Halkali, Istanbul, Turkey
²Department of Cardiology, Usak State Hospital, Usak, Turkey
³Department of Cardiology, Istanbul Education and Research Hospital, Istanbul, Turkey
⁴Department of Biochemistry, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Halkali, Istanbul, Turkey
⁵Department of Cardiology, Bakirkoy Dr Sadi Konuk Education and Research Hospital, Bakirkoy, Istanbul, Turkey

Postep Kardiol Inter 2014; 10, 1(35):12–17
DOI: 10.5114/pwki.2014.41460

Abstract

Introduction: Insulin-like growth factor-1 (IGF-1) has atheroprotective effects via reduction in oxidative stress, cellular apoptosis, pro-inflammatory signaling, and endothelial dysfunction.

Aim: We hypothesized that low levels of IGF-1 may be associated with the severity and extent of coronary artery disease and development of the coronary no-reflow phenomenon in patients with acute ST-elevation myocardial infarction (STEMI) and investigated the role of the IGF-1 molecule in the coronary no-reflow phenomenon and severity of coronary artery disease (CAD) in patients with acute STEMI in a tertiary hospital.

Material and methods: The study was conducted among 113 patients undergoing primary percutaneous coronary intervention (PPCI) for STEMI, of whom 49 patients developed the no-reflow phenomenon. Coronary no-reflow was defined as Thrombolysis In Myocardial Infarction (TIMI) flow grade 2 or less after intervention. Insulin-like growth factor-1 levels were measured in both groups. The severity and extent of CAD were evaluated according to the Gensini and Syntax scores.

Results: Although IGF-1 levels were lower in the no-reflow group, there was not a statistically significant difference between the no-reflow group and the control group (116.65 ±51.72 vs. 130.82 ±48.76, p = 0.130). Gensini and Syntax scores were higher in the no-reflow group. There was no association between Gensini and Syntax scores and IGF-1 levels (r = –0.071, r = 0.479, r = –0.158, p = 0.113).

Conclusions: In this study, IGF-1 levels were not statistically different between patients developing the no-reflow phenomenon and controls. There was no association between development of the no-reflow phenomenon and severity of CAD or IGF-1 levels. Nevertheless, large scale studies are needed to verify these results.

Key words: insulin-like growth factor-1, no-reflow, coronary artery disease, ST-elevation myocardial infarction.

Introduction

Insulin-like growth factor-1 (IGF-1) has anti-inflammatory and pro-repairing properties that make it antithero-genic [1, 2]. Circulating IGF-1 is mainly released by the liver under the regulation of growth hormone and executes all of its physiological effects via binding to its receptor [2]. To date, several studies have already described the importance of IGF-1 on atherosclerosis with its large biological effects and therapeutic potential. Although the results of these trials are inconclusive, in general, there is an inverse relation between IGF-1 levels and atherosclerosis [2, 3]. Insulin-like growth factor-1 reduces oxidative stress, inflammation and atherogenesis in the vasculature and plays a major role in vasodilatory responses by regulating nitric oxide (NO) production in the endotheli-
The angiographic no-reflow phenomenon is defined as severely impaired forward coronary flow (Thrombolysis in Myocardial Infarction (TIMI) < 3) in the absence of residual stenosis, dissection or thrombosis [5–9]. Although the underlying mechanisms of no-reflow remain obscure, microvascular plugging, thrombotic debris, cellular edema, reperfusion injury, endothelial dysfunction, coronary vasospasm and microvascular spasm are likely to be closely related [4, 6, 7, 10]. The prevalence of no-reflow varies from 2% to 50%, depending on the definition, recognition methods and selected patient population [6, 11]. Patients with no-reflow tend to experience more early post-infarction complications, heart failure, cardiogenic shock and death [4, 6, 10, 11]. According to our knowledge, there is no study investigating the interactions between IGF-1 levels and development of the no-reflow phenomenon in English literature.

**Aim**

Thus, we hypothesized that low levels of IGF-1 may be associated with the severity and extent of coronary artery disease (CAD) and development of the coronary no-reflow phenomenon in patients with acute ST-elevation myocardial infarction and investigated the role of the IGF-1 molecule in the coronary no-reflow phenomenon and severity of CAD in patients with acute STEMI in a tertiary hospital.

**Material and methods**

**Study patients**

This is an observational, case-control comparative study. Patients with STEMI who underwent PPCI within 90 min after first medical contact were included. A total of 113 patients were selected for enrollment in the trial. Forty-nine patients developed no-reflow (group 1). Sixty-four patients did not (group 2). All patients were given similar medical treatment according to related guideline directed medical treatment approaches except for no-reflow treatment. Exclusion criteria were cardiogenic shock, complete AV block on admission, rescue percutaneous coronary intervention (PCI), intervention on vein grafts, coronary dissection, angiographically visible distal embolization, severe heart failure, severe bronchospastic disease, patients with previous percutaneous revascularization and/or myocardial infarction, severe renal failure (creatinine > 3 mg) and liver failure. Diabetic patients on insulin therapy or poorly controlled diabetic patients (such as diabetic ketoacidosis and hyperosmolar nonketotic coma), patients with acromegaly or growth hormone deficiency, patients on steroid therapy and patients with known malignancy were also excluded.

All patients provided written informed consent and the study protocol was approved by the ethics committee of the hospital in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.

**Insulin-like growth factor-1 measurement**

Arterial blood (20 ml) was collected from the femoral artery sheath after completing primary percutaneous intervention. After the collection, the tubes were centrifuged at 3000 rpm for 10 min and the serum transferred to capped tubes for storage. All aliquots were anonymized and stored frozen at −40°C for 6 months until analyzed. All analyses were performed using Siemens Immulite IGF-I assay with solid-phase enzyme labeled chemiluminescent immunometric assay [12]. Hemolyzed, lipemic and icteric sera were not used for analysis. The result of the IGF1 test was given in ng/ml.

**Coronary angiography**

All angiograms were performed with 7 Fr guiding catheters without side holes at a speed of 30 frames per second. Coronary angiography was carried out by an automatic mechanical injector (ACIST CVi, Bracco Imaging S.p.A. Italy). All observations were performed by an interventional cardiologist who was blinded to the study groups. The TIMI flow score was defined by the degree of flow into the epicardial artery as follows: grade 0, complete absence of flow beyond the point of obstruction; grade 1, some contrast material flows distal to the obstruction but complete arterial visualization is not achieved; grade 2, delayed opacification of the entire artery; and grade 3, full prompt visualization of the entire artery [13].

**Coronary artery disease scoring**

The severity and extent of CAD were evaluated according to the Gensini score and Syntax score. Gensini score depends on the degree of the coronary artery stenosis and its geographic importance [14]. The degree of luminal narrowing, concentricity and eccentricity of the plaques are evaluated. 1 point is given for 1–25% stenosis, 2 points for 26–50%, 4 points for 51–75%, 8 points for 76–90%, 16 points for 91–99%, and 32 points for 100% stenosis. Further, each lesion’s point is multiplied by the coefficient which is given for each principal vascular segment due to the functional significance (the left main coronary artery × 5; the proximal segment of the left anterior descending coronary artery (LAD) × 2.5; the proximal segment of the circumflex artery × 2.5; the mid-segment of the LAD × 1.5; the right coronary artery, the distal segment of the LAD, the posterolateral artery and the obtuse marginal artery × 1; and others × 0.5), and the sum of all gives the total score [14]. The Syntax score corresponding to the lesion complexity was measured by the coronary tree characteristics and the lesion locations.
and specifics [15]. The score is measured using the openly accessible web based score calculator (http://www.syn-taxscore.com). Scorings were performed and averaged by two observers who were blinded to the study groups.

**Statistical analysis**

Statistical calculations were performed with Number Cruncher Statistical System 2007 Statistical Software program for Windows (Utah, USA). Besides standard descriptive statistical calculations (mean and standard deviation, median, interquartile range), for the variables that showed a normal distribution, the unpaired t test was used in the comparison of groups, for the variables not having a normal distribution, the Mann-Whitney U test was used in the comparison of groups, and the χ² test was performed during the evaluation of qualitative data. The Pearson correlation test was used to determine the relationships between the variables. The statistical significance level was established at \( p < 0.05 \).

**Results**

Patient and control groups were similar in terms of sex, age, body mass index, presence of diabetes and hypertension and family history of coronary artery disease. Patients’ characteristics, differences and study results are presented in Table I. Although IGF-1 levels tend to be lower in no-reflow patients, results were not statistically different between the no-reflow group and the control group (116.65 ±51.72 vs. 130.82 ±48.76, \( p = 0.130 \)). In-hospital mortality was higher in the no-reflow group (8.77% vs. 0%, \( p = 0.016 \)). Gensini and Syntax scores were lower in the control group. However, there was no correla-

| Parameter                  | No-reflow (n = 49) | Lack of no-reflow (n = 64) | Value of p |
|---------------------------|-------------------|---------------------------|------------|
| Age [years]               | 58.16 ±12.35      | 55.03 ±8.98               | 0.111      |
| Sex, n (%) Male           | 41 (83.67)        | 56 (87.50)                | 0.596      |
|                          | Female            | 8 (16.33)                 | 8 (12.50)  |
| BMI [kg/m²]               | 28.13 ±4.13       | 27.75 ±4.98               | 0.732      |
| Diabetes mellitus, n (%)  | 10 (20.41)        | 10 (15.63)                | 0.680      |
| Hypertension, n (%)       | 15 (30.61)        | 20 (31.25)                | 0.942      |
| Hyperlipidemia, n (%)     | 12 (24.49)        | 11 (17.19)                | 0.471      |
| Alcohol use, n (%)        | 4 (8.16)          | 13 (20.31)                | 0.127      |
| Smoking, n (%)            | 21 (42.86)        | 49 (76.56)                | 0.005      |
| Family history of CAD, n (%) | 19 (38.78)     | 31 (48.44)                | 0.404      |
| In-hospital mortality, n (%) | 5 (10.20)     | 0 (0.00)                  | 0.031      |
| IGF-1                     | 116.65 ±51.72     | 130.82 ±48.76             | 0.130      |
| Gensini score             | 67.4 ±26.85       | 47.13 ±24.8               | 0.0001     |
| Syntax score              | 25.48 ±10.3       | 17.94 ±8.03               | 0.0001     |
| Number of stents          | 1.45 ±0.71        | 1.16 ±0.6                 | 0.019      |
| Stent diameter            | 3.33 ±0.47        | 2.98 ±0.86                | 0.013      |
| Stent length              | 30.04 ±16.14      | 23.5 ±12.13               | 0.015      |
| Glucose                   | 177.16 ±94.42     | 144.87 ±74.78             | 0.041      |
| Total cholesterol         | 193.73 ±37.53     | 204.24 ±48.3              | 0.204      |
| Triglyceride              | 109.87 ±61.58     | 151.52 ±87.44             | 0.005      |
| LDL                        | 126.61 ±33.59     | 141.43 ±42.72             | 0.044      |
| HDL                       | 45.93 ±12.43      | 39.66 ±9.78               | 0.004      |
| Creatinine                | 0.93 ±0.32        | 0.84 ±0.17                | 0.4       |
| Troponin max.             | 16.02 ±14.95      | 6.52 ±8.04                | 0.0001     |
| EF                         | 41.5 ±9.75        | 51.05 ±8.84               | 0.0001     |
| RDW                       | 13.3 ±1.08        | 13.1 ±1                   | 0.301      |
| Platelet count            | 248.05 ±61.81     | 258.19 ±56.09             | 0.350      |
| MPV                       | 8.21 ±0.86        | 8.47 ±0.83                | 0.096      |
| Neutrophil count          | 10325.18 ±3950.56 | 8754.76 ±3428.08          | 0.022      |
| Lymphocyte count          | 1681.25 ±1027.61  | 2150.08 ±914.42           | 0.01       |
| NLR                       | 8.57 ±7.25        | 5.29 ±3.94                | 0.002      |
endothelium. Endothelial dysfunction, coronary vaso-
spasm and microvascular spasm may play a role in the 
endothelin-1 induced contractile responses in the vascular 
development of the no-reflow or slow flow phenomenon. 
Insulin-like growth factor-1 also has positive effects on 
vascular homeostasis [2, 3, 16]. Nitric oxide plays an im-
portant role in the regulation of endothelial function due 
to its potent vasodilator effect and sensitivity of redox sta-
tus of the endothelium [2]. Increasing evidence indicates 
that IGF-1 preserves endothelial function and plays a ma-
jor role in vasodilatory responses by increasing NO pro-
duction and decreasing oxidative stress and attenuating 
endothelin-1 induced contractile responses in the vascular 
endothelium [2]. Endothelial dysfunction, coronary vaso-
spasm and microvascular spasm may play a role in the 
pathogenesis of the no-reflow phenomenon. Although IGF-1 
levels tended to be lower in no-reflow patients in 
our study, there was no statistically significant association 
between development of the no-reflow phenomenon and 
IGF-1, which has potential vasodilator effects on vascular 
function. Although microvascular dysfunction is one of the 
possible pathophysiological mechanisms for the no-reflow 
phenomenon [4, 6, 7, 10], thrombus burden and athero-
sclerotic debris burden may play a more effective role in 
development of the no-reflow or slow flow phenomenon. 
According to the results of our study, IGF-1 may not have 
significant contribution to the development of no-reflow 
or slow flow in patients with STEMI. Insulin-like growth 
factor-1 also has positive effects on the development of 
cardiac structures, myocardial contraction, heart beats 
and ejection fraction and increases cardiac performance 
and decreases wall tension [17]. Animal studies have 
shown that IGF-1 has the ability to reduce the atheroscle-
rotic burden by its pleiotropic, antioxidant and antiinflam-
atory effects [1, 2]. Low IGF-1 expression and/or bioavail-
ability may play a role in oxidized LDL induced cytotoxicity 
and apoptosis in vascular smooth muscle cells that help 
plaque destabilization and rupture [3]. High IGF-1, with its 
receptor and binding proteins, may protect the atheroscle-
rotic plaque against destabilization and rupture [16]. The 
receptor of IGF-1 creates a hybrid receptor with the insulin 
receptor, resulting in more IGF-1 expression, which makes 
vascular smooth muscle cells insensitive to insulin [2]. Low 
levels of IGF-1 are associated with chronic insulin resis-
tance and impaired glucose tolerance [16, 18]. Insulin-like 
growth factor-1 levels are also lower in patients with poorly 
controlled diabetes [1]. According to several studies, IGF-1 
levels are correlated with cardiovascular disease risk in 
the general population [16], It has been reported that low 
levels of IGF-1 may be an independent risk factor for myo-
cardial infarction, coronary artery disease and increased 
carotid intima-media thickness, and interfere with obe-
sity, insulin resistance, impaired glucose intolerance and 
left ventricular hypertrophy [18]. However, clinical studies 
have produced conflicting results regarding the relation 
between IGF-1 and different forms of CAD [1, 18–20]. Spalla-
rossa et al. observed decreased IGF-1 levels in patients 
with advanced CAD [21]. Burchardt et al. determined higher 
IGF-1 levels in patients with advanced CAD than patients 
with hemodynamically insignificant CAD [16]. They stated 
that high IGF-1 levels are a physiological regulatory mecha-
nism against CAD. Patients with high IGF-1 levels experi-
ence more stable angina than acute coronary syndromes 
[22]. Ruotolo et al. demonstrated an independent associa-
tion between IGF-1 levels and progression of CAD in young 
males survivors of MI [23]. However, Botker et al. could not 
show an association between IGF-1 levels and CAD [24]. 
Similarly, Lawlor et al. could not show any association be-
 tween IGF-1 levels and coronary artery disease [25]. In our 
study, there was no association between IGF-1 levels and 
the extent and severity of CAD. There was no association 
between the no-reflow phenomenon and IGF-1 levels, also, 
despite the reports asserting that IGF-1 plays an important 
role in arterial vasodilatation by controlling endothelial NO 
production and reduces inflammation and oxidative stress 
[2, 17]. Changes in lipid profile after acute coronary syn-
drome have been known for at least 50 years [26]. While 
total cholesterol, LDL and HDL levels tend to decrease by 
0–20%, triglyceride levels increase by 20–30% [26, 27]. 
Stress-induced myocardial damage alerts adrenergic activa-
tion associated lipolysis and mobilizes free fatty acids 
[26, 27]. Likewise, LDL levels were lower in patients with 
no-reflow than controls in our study. Higher creatinine lev-
els detected in the no-reflow group may be associated with
impaired coronary flow. Interestingly, current smokers had the no-reflow phenomenon less often in our study. According to our study, neutrophil count and NLR may also predict no-reflow, which may be explained by an excessive inflammatory response in no-reflow patients. The NLR index is known to specify the inflammatory status [28]. The NLR has recently been shown as a predictor of mortality in patients with acute myocardial infarction, stable patients with CAD and in patients undergoing PCI and all other conditions [28, 29]. In-hospital mortality was higher in the no-reflow group, who have higher levels of neutrophil counts and NLR in this study. The number, length and diameter of stents used were higher in no-reflow patients, also.

Study limitations: Since this was a single-center study limited to PPCI of native vessels, the number of patients was small, representing the major limitation. Another limitation of our study is that unfortunately we do not have enough sound data about balloon inflation pressures and patients’ previous medications. Another issue is the high frequency of the no-reflow phenomenon in our study population, approximately 50% of all patients. It is high as compared to data of other large scale studies, even on STEMI patients only [30]. This may be related to the methodology of evaluation and definition of no-reflow. Since the no-reflow group included patients with higher Gensini and Syntax scores, the slower flow might be related to some residual stenoses within the infract-related artery. Unfortunately, we were not able to use thrombus aspiration catheters during the study period; manual thrombus aspiration might have changed our results. In the CathPCI Registry, Harrison et al. reported that older age, STEMI, prolonged interval from symptom onset to intervention, cardiogenic shock, longer lesion length, higher risk class C lesions, bifurcation lesions, and periprocedural TIMI flow grade were clinical and angiographic variables independently associated with development of the no-reflow phenomenon [30]. Since the no-reflow phenomenon was blindly evaluated, possible differences do not change the value of results. However, large scale multicenter studies may reveal different results.

Conclusions

In this study, although no-reflow or slow flow was mostly seen in patients with more diffuse and severe CAD, there was no association between development of the no-reflow phenomenon and the severity of CAD or IGF-1 levels. However, large scale studies are needed to verify these results.

References

1. Sukhanov S, Higashi Y, Shai SY, et al. IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27: 2684–2690.

2. Higashi Y, Sukhanov S, Anwar A, et al. Aging, atherosclerosis, and IGF-1. J Gerontol A Biol Sci Med Sci 2012; 67: 626–639.

3. Burchardt P, Gozdzicka-Jozefiak A, Zurawski I, et al. Are elevated levels of IGF-1 caused by coronary arteriesclerosis? Molecular and clinical analysis. Protein J 2010; 29: 538–544.

4. Rezkalla SH, Dharmashankar KC, Abdalrahman IB, Kloner RA. No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome and effect of pharmacologic therapy. J Interv Cardiol 2010; 23: 429–436.

5. Tanszilli G, Greco C, Pascrei V, et al. Dipyridamole versus verapamil for treatment of no-reflow during primary angioplasty. Catheter Cardiovasc Interv 2010; 76: 787–793.

6. Niccoli G, Marino M, Spaziani C, Crea F. Prevention and treatment of no-reflow. Acute Card Care 2010; 12: 81–91.

7. Werner GS, Lang K, Kuehner H, Figulla HR. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv 2002; 57: 444–451.

8. Gibson MC, Schomig A. Coronary and myocardial angiography. Angiographic assessment of both epicardial and myocardial perfusion. Circulation 2004; 109: 3096–3105.

9. Petronio AS, De Carlo M, Cibatti N, et al. Left ventricular remodeling after primary coronary angioplasty in patients treated with abiximab or intracoronary adenosine. Am Heart J 2005; 150: 1015.

10. Bhaavasar J, Rosenson R. Adenosine transport, erythrocyte deformability and microvascular dysfunction: an unrecognized potential role for dipyridamole therapy. Clin Hemorheol Microcirc 2010; 44: 193–205.

11. Plana RN, Paik GY, Moscucci M, et al. Incidence and treatment of no reflow after percutaneous coronary intervention. Circulation 1994; 89: 2514–2518.

12. Krebs A, Wallaschofski H, Spilcke-Liss E, et al. Five commercially available insulin-like growth factor I (IGF-I) assays in comparison to the former Nichols Advantage IGF-I in a growth hormone treated population. Clin Chem Lab Med 2008; 46: 1776–1783.

13. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase 1 findings. N Engl J Med 1985; 312: 932–936.

14. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51: 606.

15. Siannos G, Morel MA, Kappestein AP, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005; 1: 219–227.

16. Burchardt P, Tabaczewski P, Gozdzicka-Jozefiak A, et al. Association between insulin like growth factor-I and lipoprotein metabolism in stable angina patients on statin therapy: a pilot study. Kardiol Pol 2012; 70: 1017–1102.

17. Şekuri C, Arslan Ö, Ütkük O, et al. Serum level of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in acute coronary syndromes and relationship with prognosis. Anadolu Kardiyol Derg 2004; 4: 209–212.

18. Colao A, Spiezia S, Di Somma C, et al. Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age. J Endocrinol Invest 2005; 28: 440–448.

19. Prêle CM, Reichelt ME, Mutsaers SE, et al. Insulin-like growth factor-I overexpression in cardiomyocytes diminishes ex vivo heart functional recovery after acute ischemia. Cardiovasc Pathol 2012; 21: 17–27.

20. Li J, Stenbøg E, Bush A, et al. Insulin-like growth factor I improves the relationship between systemic oxygen consumption
Ibrahim Faruk Akturk et al. Role of IGF-1 on no-reflow and CAD severity

and delivery in piglets after cardiopulmonary bypass. J Thorac Cardiovasc Surg 2004; 127: 1436–1441.

21. Spallarossa P, Brunelli C, Minuto F, et al. Insulin-like growth factor-I and angiographically documented coronary artery disease. Am J Cardiol 1996; 77: 200–202.

22. Conti E, Andreotti F, Sciahbasi A, et al. Markedly reduced insulin-like growth factor-I in the acute phase of myocardial infarction. J Am Coll Cardiol 2001; 38: 26–32.

23. Ruotolo G, Bävenholm P, Brismar K, et al. Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment. J Am Coll Cardiol 2000; 35: 647–654.

24. Botker HE, Skjaerbaek C, Eriksen UH, et al. Insulin-like growth factor-I, insulin, and angina pectoris secondary to coronary atherosclerosis, vasospasm, and syndrome X. Am J Cardiol 1997; 79: 961–963.

25. Lawlor AD, Ebrahim S, Smith GD, et al. The association of insulin-like growth factor 1 (IGF-1) with incident coronary heart disease in women: findings from the prospective British Women’s Heart and Health Study. Atherosclerosis 2008; 201: 198–204.

26. Miller M. Lipid levels in the post-acute coronary syndrome setting. J Am Coll Cardiol 2008; 51: 1446–1447.

27. Pitt B, Loscalzo J, Ycuas J, Raichlen JS. Lipid levels after acute coronary syndromes. J Am Coll Cardiol 2008; 51: 1440–1445.

28. Sönmez O, Ertaş G, Bacaksız A, et al. Relation of neutrophil-to-lymphocyte ratio with the presence and complexity of coronary artery disease: an observational study. Anadolu Kardiyol Derg 2013; 13: 662–7.

29. Balta S, Demirkol S, Unlu M, et al. Neutrophil to lymphocyte ratio may be predictor of mortality in all conditions. Br J Cancer 2013; 109: 3125–6.

30. Harrison RW, Aggarwal A, Ou FS, et al.; American College of Cardiology National Cardiovascular Data Registry. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am J Cardiol 2013; 111: 178–184.